As part of the deal, both the firms will carry out collaborative research using the J-Brain Cargo technology and certain pharmaceutical candidate compounds of Eisai’s choice, to develop
Asahi has the rights to develop and market Xiaflex in Japan through an agreement with BioSpecifics’ partner Endo International (Endo). In return, BioSpecifics will be eligible for receiving
The trial is designed to evaluate both the safety and efficacy of human neural stem cells for the treatment of geographic atrophy (GA), the most advanced form of
Intrahepatic cholangiocarcinoma (ICC), a sub-category of cholangiocarcinoma, is a tumor in the bile duct that arises within the liver and it is the second most common primary liver
The trial showed positive Data Safety Monitoring Board (DSMB) safety review following the treatment of the first 24 patients with ERY-ASP. Around 90 people were included in this
The open-label, randomized trial was ended early because of the assessment data reported by the independent Data Monitoring Committee (DMC). The data showed that the trial met its
The authorization follows the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) in May this year, which was based on a review of
The company noted that all patients who complete the APOLLO Phase III trial with patisiran are eligible for enrollmnet in APOLLO-OLE. The trial is designed to assess the
Iclaprim is designed to be effective against multi-drug resistant bacteria. The company requested QIDP designation for Iclaprim for two serious and life threatening infections, HABP and acute bacterial
In March this year, the company secured approval from the US Food and Drug Administration (FDA) for Saphris for the acute treatment of manic or mixed episodes associated
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.